var data={"title":"Oseltamivir: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oseltamivir: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6690?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oseltamivir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oseltamivir: Patient drug information&quot;</a> and <a href=\"topic.htm?path=oseltamivir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oseltamivir: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50907063\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=9460\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=9460\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204115\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tamiflu</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204116\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tamiflu</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204138\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiviral Agent;</li>\n      <li>\n        Neuraminidase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204118\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Influenza prophylaxis:</b> Oral: 75 mg once daily; initiate prophylaxis within 48 hours of contact with an infected individual; duration of prophylaxis: 10 days (manufacturer recommendation) or alternatively 7 days (CDC [Influenza Antiviral Medications] 2014).  During community outbreaks, duration of protection lasts for length of dosing period; safety and efficacy have been demonstrated for use up to 6 weeks in immunocompetent patients and safety has been demonstrated for use up to 12 weeks in patients who are immunocompromised.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Prophylaxis, institutional outbreak (CDC [Influenza Antiviral Medications] 2014):</i> Continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Influenza treatment:</b> Oral: 75 mg twice daily initiated within 48 hours of onset of symptoms; usual duration of treatment: 5 days.  However, optimal duration is uncertain for severe or complicated influenza. Consider longer duration (eg, &gt;5 days) of therapy in severely ill patients who remain severely ill after 5 days of therapy (CDC [Influenza Antiviral Medications] 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b>  Data suggest that increased doses (&gt;150 mg daily) in critically ill patients is not necessary since blood concentrations of oseltamivir were comparable or higher compared to ambulatory patients given similar dosing regimens (Ariano 2010; CDC [Influenza Antiviral Medications] 2014). Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza regardless of the time of presentation from symptom onset (even if  &gt;48 hours) (CDC [Influenza Antiviral Medications] 2014); may be administered via naso- or orogastric tube in mechanically-ventilated patients (Taylor 2008). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Critically ill: Concurrent use of extracorporeal membrane oxygenation (ECMO) alone:</i> No dosage adjustment necessary (Lemaitre 2012; Mulla 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204130\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=oseltamivir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oseltamivir: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia (influenza suspected or confirmed) (off-label use) (IDSA [Bradley 2011]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 3 to 8 months: 3 mg/kg/day once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;9 months to Children &le;23 months: 3.5 mg/kg/day once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates and Infants &le;8 months: 6 mg/kg/day in divided doses twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;9 months to Children &le;23 months: 7 mg/kg/day in divided doses twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Influenza prophylaxis:</b> Oral: Initiate prophylaxis within 48 hours of contact with an infected individual</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 1 to 12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;15 kg: 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;15 kg to &le;23 kg: 45 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;23 kg to &le;40 kg: 60 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;40 kg: 75 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;13 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">American Academy of Pediatrics: Infants 0 to 11 months (off-label dosing; AAP 2013):<b> Note:</b> Do not exceed maximum dose of weight-based dosing; see manufacturer's recommendation. Prophylaxis is not recommended for infants &lt;3 months of age unless clinically critical.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">0 to 8 months: 3 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">9 to 11 months: 3.5 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Centers for Disease Control: Infants &lt;12 months (off-label dosing) (CDC [Influenza Antiviral Medications] 2014): 3 mg/kg/dose once daily. <b>Note:</b> Do not exceed maximum dose of weight-based dosing; see manufacturer&rsquo;s recommendation. Prophylaxis is not recommended for infants &lt;3 months of age unless clinically critical. The current CDC weight-based dosing recommendation is not intended for premature neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infectious Disease Society of America/Pediatric Infectious Disease Society: Infants and Children 3 to 23 months (off-label dosing; Bradley 2011): <b>Note:</b> Do not exceed maximum dose of weight-based dosing; see manufacturer's recommendation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3 to 8 months: 3 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">9 to 23 months: 3.5 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Prophylaxis duration:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Individual/household exposure:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer's labeling:</i> 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate recommendations:</i> 7 days (CDC [Influenza Antiviral Medications] 2014); 10 days (AAP 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Community/institutional outbreak: <b>Note:</b> The prescribing information states that during community outbreaks, duration of protection lasts for length of dosing period; safety and efficacy have been demonstrated for use up to 6 weeks in immunocompetent patients and safety has been demonstrated for use up to 12 weeks in patients who are immunocompromised.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer's labeling:</i> May be used for up to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate recommendations:</i> Continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient (CDC [Influenza Antiviral Medications] 2014) or until influenza activity in community subsides or immunity obtained from immunization (Bradley 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Influenza treatment:</b> Oral: Initiate treatment within 48 hours of onset of symptoms; usual duration of treatment is 5 days. However, optimal duration is uncertain for severe or complicated influenza. Consider longer duration (eg, &gt;5 days) of therapy in severely ill patients who remain severely ill after 5 days of therapy. <b>Note:</b> Data suggest that increased doses in critically ill patients is not necessary since blood concentrations of oseltamivir were comparable or higher compared to ambulatory patients given similar dosing regimens (Ariano 2010; CDC [Influenza Antiviral Medications] 2014). Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza regardless of the time of presentation from symptom onset (even if &gt;48 hours) (CDC [Influenza Antiviral Medications] 2014); may be administered via naso- or orogastric tube in mechanically-ventilated patients (Taylor 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US manufacturer's labeling:</i> <b>Note:</b> The following dosing is also supported by some clinicians (Bradley 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;2 weeks: 3 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 1 to 12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;15 kg: 30 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;15 kg to &le;23 kg: 45 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;23 kg to &le;40 kg: 60 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;40 kg: 75 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;13 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">American Academy of Pediatrics: Infants &lt;12 months (off-label dosing; AAP 2013): <b>Note:</b> Age defined as postmenstrual age (first day of mother's last period to birth plus the time elapsed after birth). Weight-based dosing recommendations for premature infants are lower than for term infants. Do not exceed maximum dose of weight-based dosing; see manufacturer's recommendation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, premature:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;38 weeks: 1 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">38 to 40 weeks: 1.5 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 weeks: 3 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, term:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">0 to 8 months: 3 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">9 to 11 months: 3.5 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Centers for Disease Control: Infants &lt;2 weeks (off-label dosing) (CDC [Influenza Antiviral Medications] 2014): 3 mg/kg/dose twice daily. <b>Note:</b> Do not exceed maximum dose of weight-based dosing; see manufacturer's recommendation. The current CDC weight-based dosing recommendation is not intended for premature neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infectious Disease Society of America/Pediatric Infectious Disease Society: Infants and Children &lt;24 months (off-label dosing; Bradley 2011): <b>Note:</b> Do not exceed maximum dose of weight-based dosing; see manufacturer's recommendation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, premature: 1 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">0 to 8 months: 3 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">9 to 23 months: 3.5 mg/kg/dose twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204119\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204120\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to 60 mL/minute: 30 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;10 to 30 mL/minute: 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD not undergoing dialysis: Use is not recommended (has not been studied)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 to 60 mL/minute: 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;10 to 30 mL/minute: 30 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD not undergoing dialysis: Use is not recommended (has not been studied)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intermittent hemodialysis (IHD) (CrCl &le;10 mL/minute):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 30 mg immediately and then 30 mg after every hemodialysis session for 5 days. <b>Note:</b> Assumes three hemodialysis sessions in the 5-day period.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternative recommendations:</i> Treatment (AMMI Canada [Aoki 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low-flux hemodialysis: 30 mg after each dialysis session for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High-flux hemodialysis: 75 mg after each dialysis session for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: 30 mg immediately and then 30 mg after every other hemodialysis sessions for the recommended prophylaxis duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;1 year of age (off-label dose; Schreuder 2010): Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;15 kg: 7.5 mg after each hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;15 kg to &le;23 kg: 10 mg after each hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;23 kg to &le;40 kg: 15 mg after each hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: 30 mg after each hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Continuous ambulatory peritoneal dialysis  (CAPD):</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: 30 mg immediately as a single dose (single dose provides a 5-day duration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis: 30 mg immediately and then 30 mg once weekly for the recommended prophylaxis duration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> For patients receiving aggressive automated peritoneal dialysis (APD) with negligible or low residual renal function, a small pharmacokinetic study suggests that 75 mg as a single dose for treatment would produce drug exposure at the upper limit of the safety margin (Patel 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Continuous renal replacement therapy (CRRT) (high-flux):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment (off-label dose; limited data): 30 mg once daily for 5 days or 75 mg every 48 hours to provide a 5-day duration (AMMI Canada [Aoki 2012]; Ariano 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis (off-label): No data (AMMI Canada [Aoki 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Continuous veno-venous hemodialysis (CVVHD):</b> Adults: <b>Note:</b> Limited information available; optimal dosing has not been established: 150 mg twice daily administered via nasogastric or postpyloric feeding tube for suspected or confirmed H1N1 influenza demonstrated supratherapeutic oseltamivir carboxylate concentrations at effluent rates of 3,300 &plusmn; 919 mL/hour; the authors determined that the manufacturer recommended dosage of 75 mg once daily for patients with CrCl 10 to 30 mL/minute will likely achieve concentrations necessary to inhibit viral neuraminidase activity at these effluent rates; however, doses &gt;75 mg once daily may be required when using higher effluent rates (Eyler 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CVVHD and concurrent use of ECMO</i>: Adults: Lower oseltamivir carboxylate concentrations (~981 ng/mL) were observed as compared to those with the use of CVVHD alone (~2,760 ng/mL) when patients were administered 150 mg twice daily for suspected or confirmed H1N1 influenza (n=4; Eyler 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204121\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21674739\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;margin-top:0em;display:inline\">In adult morbidly obese patients (BMI &gt;40 kg/m<sup>2</sup>), systemic exposure of oseltamivir carboxylate was not reduced; therefore, no dosage adjustment is necessary (Thorne-Humphrey 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204091\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tamiflu: 30 mg, 45 mg, 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg, 45 mg, 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tamiflu: 6 mg/mL (60 mL) [contains saccharin sodium, sodium benzoate, sorbitol; tutti-frutti flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 mg/mL (60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204077\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5383845\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to meals; take with food to improve tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules may be opened and mixed with sweetened liquid (eg, chocolate syrup, corn syrup, caramel topping, light brown sugar dissolved in water). Administer oral suspension using an oral dosing dispenser that measures the appropriate volume in milliliters; shake well before each use. When oral suspension is not available and/or age-appropriate strength of capsules are not available to mix with sweetened liquids, an extemporaneous preparation may be prepared (refer to &ldquo;extemporaneously prepared&rdquo; section of monograph for further details).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mechanically ventilated critically ill patients: May administer via naso- or orogastric (NG/OG) tube. Dissolve powder from capsules in 20 mL of sterile water and inject down the NG/OG tube; follow with a 10 mL sterile water flush (Taylor 2008). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204092\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of influenza:</b> Prophylaxis of influenza (A or B) infection in patients &ge;1 year of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Treatment of influenza:</b> Treatment of uncomplicated acute illness due to influenza (A or B) infection in patients &ge;2 weeks of age who have been symptomatic for no more than 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends that <b>treatment</b> be considered for the following: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons with severe, complicated or progressive illness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized persons</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons at higher risk for influenza complications:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Children &lt;2 years of age (highest risk in children &lt;6 months of age)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- \tAdults &ge;65 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons with chronic disorders of the pulmonary (including asthma) or cardiovascular systems (except hypertension)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons with chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders (including sickle cell disease), or immunosuppression (including immunosuppression caused by medications or HIV)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-\tPersons with neurologic/neuromuscular conditions (including conditions such as spinal cord injuries, seizure disorders, cerebral palsy, stroke, mental retardation, moderate to severe developmental delay, or muscular dystrophy) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Pregnant or postpartum women (&le;2 weeks after delivery)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-\tPersons &lt;19 years of age on long-term aspirin therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- American Indians and Alaskan Natives</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- \tPersons who are morbidly obese (BMI &ge;40)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Residents of nursing homes or other chronic care facilities</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Use may also be considered for previously healthy, nonhigh-risk outpatients with confirmed or suspected influenza based on clinical judgment when treatment can be started within 48 hours of illness onset. </p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">The ACIP recommends that <b>prophylaxis</b> be considered for the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Postexposure prophylaxis may be considered for family or close contacts of suspected or confirmed cases, who are at higher risk of influenza complications, and who have not been vaccinated against the circulating strain at the time of the exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postexposure prophylaxis may be considered for unvaccinated healthcare workers who had occupational exposure without protective equipment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Pre-exposure prophylaxis should only be used for persons at very high risk of influenza complications who cannot be otherwise protected at times of high risk for exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">&bull; Prophylaxis should also be administered to all eligible residents of institutions that house patients at high risk when needed to control outbreaks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\"> The ACIP recommends that treatment and prophylaxis be given to children &lt;1 year of age when indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Limitations of use:</b> Not a substitute for annual influenza vaccination. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate oral. Not recommended for patients with end-stage renal disease not undergoing dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860706\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Community-acquired pneumonia (children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204146\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tamiflu may be confused with Tambocor, Thera-Flu</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oseltamivir (Tamiflu) oral suspension is available in a 6 mg/mL concentration. <b>Instructions to the patient should be provided based on these units of measure (ie, mL). When providing oseltamivir suspension for children &lt;1 year of age, use a lower calibrated (ie, &lt;10 mL) oral syringe to ensure accurate dosing.</b></p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">When commercially-prepared oseltamivir oral suspension is not available, an extemporaneously prepared suspension may be compounded to provide a 6 mg/mL concentration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204084\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (adolescents and adults: 2% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (2% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (adolescents and adults: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (adolescents and adults: 8% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal behavior, abnormal hepatic function tests, accidental injury, agitation, anaphylactoid reaction, anaphylaxis, anxiety, cardiac arrhythmia, confusion, delirium, delusions, dermatitis, eczema, erythema multiforme, exacerbation of diabetes mellitus, facial edema, gastrointestinal hemorrhage, hallucination, hemorrhagic colitis, hepatitis, hypersensitivity reaction, hypothermia, impaired consciousness, nightmares, seizure, skin rash, Stevens-Johnson syndrome, swollen tongue, toxic epidermal necrolysis, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204096\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to oseltamivir or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204081\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity: Rare but severe hypersensitivity reactions, including anaphylaxis and severe dermatologic reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme), have been associated with use. Discontinue use immediately if hypersensitivity occurs or is suspected and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric events: Rare occurrences of neuropsychiatric events (including confusion, delirium, hallucinations, and/or self-injury) have been reported primarily in pediatric patients from postmarketing surveillance; direct causation is difficult to establish (influenza infection may also be associated with behavioral and neurologic changes, in some cases resulting in fatal outcomes). These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease. Monitor closely for signs of any unusual behavior.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with chronic cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; safety and efficacy have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; dosage adjustment is required for patients with renal impairment. Not recommended for patients with end stage renal disease (ESRD) not undergoing dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sorbitol: Oral suspension contains sorbitol (delivers ~2 g sorbitol per 75 mg dose) which is greater than the maximum daily limit for patients with hereditary fructose intolerance; may cause diarrhea and dyspepsia; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Oseltamivir is not a substitute for the influenza virus vaccine. It has not been shown to prevent primary or concomitant bacterial infections that may occur with influenza virus. Antiviral treatment should begin within 48 hours of symptom onset. However, the CDC recommends that treatment may still be beneficial and should be started in hospitalized patients with severe, complicated or progressive illness if &gt;48 hours. Treatment should not be delayed while awaiting results of laboratory tests for influenza. Nonhospitalized persons who are not at high risk for developing severe or complicated illness and who have a mild disease are not likely to benefit if treatment is started &gt;48 hours after symptom onset. Nonhospitalized persons who are already beginning to recover do not need treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299796\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204086\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9460&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase serum concentrations of the active metabolite(s) of Oseltamivir. Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary.  Increase monitoring for adverse events, such as thrombocytopenia.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204088\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204099\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in some animal reproduction studies. Oseltamivir phosphate and its active metabolite oseltamivir carboxylate cross the placenta (Meijer 2012). An increased risk of adverse neonatal or maternal outcomes has generally not been observed following maternal use of oseltamivir during pregnancy (CDC 60[1] 2011; CDC March 13, 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Neuraminidase inhibitors are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks' postpartum (CDC 60[1] 2011; CDC March 13, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204100\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Oseltamivir and oseltamivir carboxylate (OC) are present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of oseltamivir is 0.5% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 2.5 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of oseltamivir was calculated by the authors of a study using a total milk concentration of oseltamivir plus OC (expressed as equivalent of oseltamivir) of 81.6 ng/mL, providing an estimated daily infant dose via breast milk of 0.012 mg/kg/day. This milk concentration was obtained following maternal administration of oral oseltamivir 75 mg twice daily in one lactating female who was 9 months' postpartum (Wentges-van Holthe 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204101\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take without regard to meals; take with food to improve tolerance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3467518\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs or symptoms of unusual behavior, including attempts at self-injury, confusion, and/or delirium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Critically-ill patients: Repeat rRT-PCR or viral culture may help to determine on-going viral replication</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204080\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Oseltamivir, a prodrug, is hydrolyzed to the active form, oseltamivir carboxylate (OC). OC inhibits influenza virus neuraminidase, an enzyme known to cleave the budding viral progeny from its cellular envelope attachment point (neuraminic acid) just prior to release.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204095\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Concurrent use of extracorporeal membrane oxygenation (ECMO): When used alone, ECMO has been shown not to impact oseltamivir carboxylate C<sub>max</sub> and AUC in 2 small studies (Lemaitre 2012; Mulla 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 23 to 26 L (oseltamivir carboxylate); may be significantly increased in patients receiving ECMO (Lemaitre 2012; Mulla 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: Oseltamivir carboxylate: 3%; Oseltamivir: 42% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (90%) to oseltamivir carboxylate; neither the parent drug nor active metabolite has any effect on the cytochrome P450 system</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 75% as oseltamivir carboxylate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Oseltamivir: 1 to 3 hours; Oseltamivir carboxylate: 6 to 10 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&gt;99% as oseltamivir carboxylate); feces (&lt;20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204098\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Oseltamivir Phosphate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (10): $141.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (10): $141.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (10): $154.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tamiflu Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (10): $167.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (10): $167.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (10): $182.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Oseltamivir Phosphate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/mL (60 mL): $163.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Tamiflu Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/mL (60 mL): $182.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204102\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antiflu (BD, IN);</li>\n      <li>Ao Er Fei (CN);</li>\n      <li>Ebilfumin (CZ, IE, MT);</li>\n      <li>Fluvir (IN);</li>\n      <li>GPO-A-Flu (TH);</li>\n      <li>Omiflu (BD, MY);</li>\n      <li>Oseflu (BD);</li>\n      <li>Pandeflu (BD);</li>\n      <li>Tamiflu (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VN, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2013-2014. <i>Pediatrics</i>. 2013;132(4):e1089-e1104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/23999962/pubmed\" target=\"_blank\" id=\"23999962\">23999962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aoki FY, Allen UD, Stiver HG, et al, AMMI Canada Guidelines, &quot;The Use of Antiviral Drugs for Influenza: Guidance for Practitioners 2012/2013,&rdquo; Can J Infect Dis Med Microbiol, 2012, 23(4):e79-92. Available at http://www.ammi.ca/media/48038/14791_aoki_final.pdf.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ariano RE, Sitar DS, Zelenitsky SA, et al, &ldquo;Enteric Absorption and Pharmacokinetics of Oseltamivir in Critically Ill Patients With Pandemic (H1N1) Influenza,&rdquo; <i>CMAJ</i>, 182(4):357-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20159892/pubmed\" target=\"_blank\" id=\"20159892\">20159892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR</i>. 2011; 60(1):1-28.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC health update regarding treatment of patients with influenza with antiviral medications. January 9, 2015. Available at <a href=\"http://emergency.cdc.gov/han/han00375.asp%20\" target=\"_blank\">http://emergency.cdc.gov/han/han00375.asp </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Intensive-Care Patients With Severe Novel Influenza A (H1N1) Virus Infection - Michigan, June 2009,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2009, 58(27):749-52. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5827a4.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5827a4.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/19609249/pubmed\" target=\"_blank\" id=\"19609249\">19609249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR</i>. 2011; 60(1):1-28.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.</a>.First published 2014; accessed on July 7, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Influenza Division, National Center for Immunization and Respiratory Diseases. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza --- Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Surveill Summ</i>, 2011, 60(1):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21248682/pubmed\" target=\"_blank\" id=\"21248682\">21248682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. March 13, 2014. Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eyler RF, Heung M, Pleva M, et al, &ldquo;Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis and/or Extracorporeal Membrane Oxygenation,&rdquo; <i>Pharmacotherapy</i>, 2012, 32(12):1061-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/23208833/pubmed\" target=\"_blank\" id=\"23208833\">23208833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harper SA, Bradley JS, Englund JA, et al, &ldquo;Seasonal Influenza in Adults and Children--Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2009, 48(8):1003-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/19281331/pubmed\" target=\"_blank\" id=\"19281331\">19281331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    He G, Massarella J, and Ward P, &ldquo;Clinical Pharmacokinetics of the Prodrug Oseltamivir and Its Active Metabolite Ro 64-0802,&rdquo; <i>Clin Pharmacokinet</i>, 1999, 37(6):471-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/10628898/pubmed\" target=\"_blank\" id=\"10628898\">10628898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jain S, Kamimoto L, Bramley AM, et al, &ldquo;Hospitalized Patients With 2009 H1N1 Influenza in the United States, April-June 2009,&rdquo; <i>N Engl J Med</i>, 2009, 361(20):1935-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/19815859/pubmed\" target=\"_blank\" id=\"19815859\">19815859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemaitre F, Luyt C, Roullet-Renoleau F, et al, &ldquo;Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza,&rdquo; <i>Ther Drug Monit</i>, 2012, 34:171-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/22354159/pubmed\" target=\"_blank\" id=\"22354159\">22354159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie JK, Jamieson DJ, Rasmussen SA, et al, &quot;2009 Pandemic Influenza A (H1N1) Virus Infection in Postpartum Women in California,&quot; <i>Am J Obstet Gynecol</i>, 2011, 204(2):144.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21074132/pubmed\" target=\"_blank\" id=\"21074132\">21074132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meijer WJ, Bruinse HW, van den Broek MP, Kromdijk W, Wensing AM. Oseltamivir and its active metabolite cross the placenta at significant levels. <i>Clin Infect Dis</i>. 2012;54(11):1676-1677.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/22460968 /pubmed\" target=\"_blank\" id=\"22460968 \">22460968 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulla H, Peek GJ, Harvey C, et al, &ldquo;Oseltamivir Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation Support,&rdquo; <i>Anaesth Intensive Care</i>, 2013, 41(1):66-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/23362894/pubmed\" target=\"_blank\" id=\"23362894\">23362894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okumura A, Kubota T, and Kato T, &ldquo;Oseltamivir and Delirious Behavior in Children With Influenza,&rdquo; <i>Pediatr Infect Dis J</i>, 2006, 25(6):572.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel K, Rayner CR, Giraudon M, et al. Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. <i>Brit J Clin Pharmacol.</i> 2015;79(4):624-635. doi: 10.1111/bcp.12526.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/25289522/pubmed\" target=\"_blank\" id=\"25289522\">25289522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robson R, Buttimore A, Lynn K, et al, &ldquo;The Pharmacokinetics and Tolerability of Oseltamivir Suspension in Patients on Haemodialysis and Continuous Ambulatory Peritoneal Dialysis,&rdquo; <i>Nephrol Dial Transplant</i>, 2006, 21(9):2556-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/16799169/pubmed\" target=\"_blank\" id=\"16799169\">16799169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schreuder MF, van der Flier M, Knops NB, et al, &ldquo;Oseltamivir Dosing in Children Undergoing Hemodialysis,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(10):1427-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/20397934/pubmed\" target=\"_blank\" id=\"20397934\">20397934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tamiflu (oseltamivir) [prescribing information]. South San Francisco, CA: Genentech, Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tamiflu (oseltamivir) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Limited; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor WRJ, Thinh BN, Anh GT, et al, &ldquo;Oseltamivir is Adequately Absorbed Following Nasogastric Administration to Adult Patients With Severe H5N1 Influenza,&rdquo; <i>PLoS One</i>, 2008, 3(10):e3410.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/18923671/pubmed\" target=\"_blank\" id=\"18923671\">18923671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thorne-Humphrey LM, Goralski KB, Slayter KL, et al, &ldquo;Oseltamivir Pharmacokinetics in Morbid Obesity (OPTIMO Trial),&rdquo; <i>J Antimicrob Chemother</i>, 2011, 66(9):2083-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/21700623/pubmed\" target=\"_blank\" id=\"21700623\">21700623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wentges-van Holthe N, van Eijkeren M, and van der Laan JW, &ldquo;Oseltamivir and Breastfeeding,&rdquo; <i>Int J Infect Dis</i>, 2008, 12(4):451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-drug-information/abstract-text/18243025/pubmed\" target=\"_blank\" id=\"18243025\">18243025</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9460 Version 180.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50907063\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204115\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F204116\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F204138\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F204118\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F204130\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F204119\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F204120\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F204121\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F21674739\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204091\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F204077\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5383845\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F204092\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25860706\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F204146\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204084\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204096\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204081\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299796\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204086\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204088\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204099\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F204100\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F204101\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3467518\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204080\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F204095\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F204098\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F204102\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9460|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oseltamivir-patient-drug-information\" class=\"drug drug_patient\">Oseltamivir: Patient drug information</a></li><li><a href=\"topic.htm?path=oseltamivir-pediatric-drug-information\" class=\"drug drug_pediatric\">Oseltamivir: Pediatric drug information</a></li></ul></div></div>","javascript":null}